WATERTOWN, Mass.--(BUSINESS WIRE)--Blend Therapeutics, a biotechnology company discovering and developing a new class of integrative combination medicines, announced the company’s founding and strategic mission to develop innovative combination medicines with novel pharmacological profiles designed to target distinct disease pathways with optimal efficacy and safety. Blend is founded based on its proprietary Maestro™ platform for integrative combination medicines, and the company has secured financing from top-tier venture investors, including Flagship Ventures, New Enterprise Associates and NanoDimension.
